ROS1-mutant lung cancer patient describes 15 years of survival on targeted therapy crizotinib
A patient account published by Stat News illustrates the long-term benefit — and limitations — of molecularly matched targeted treatment for ROS1-rearranged non-small-cell lung cancer.
Stat News has published a personal account from a patient living with ROS1-rearranged non-small-cell lung cancer (NSCLC) who has survived for fifteen years on crizotinib, a tyrosine kinase inhibitor originally developed for ALK-rearranged lung cancer and subsequently approved for ROS1-positive disease. The account was presented at the STAT Summit.
ROS1 gene rearrangements are found in approximately 1–2% of NSCLC cases and define a molecularly distinct subgroup for which targeted therapies offer substantially better outcomes than historical chemotherapy benchmarks. Crizotinib was the first approved agent in this setting, and the field has since seen the development of next-generation ROS1 inhibitors with improved central nervous system penetration.
The patient's account focuses on quality of life alongside survival — raising the point that long-term survivorship, and what it means for daily functioning, receives less attention in research outcomes than survival statistics. The account also describes the loss of fellow patients who did not experience the same durability of response, highlighting variability in outcomes that remains incompletely understood.
This article is primarily a first-person narrative rather than a clinical study; it is included here because it illustrates the real-world application of somatic genomic tumour profiling in directing targeted oncology treatment, an area of broad relevance to oncologists, researchers in cancer genomics, and patients.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
A person living with a type of lung cancer caused by a change in a gene called ROS1 has shared their experience of surviving for fifteen years using a targeted medicine called crizotinib. This drug works by blocking a faulty signal produced by the altered ROS1 gene, which drives cancer cell growth. ROS1 changes are found in a small proportion — roughly one to two in a hundred — of people with non-small-cell lung cancer. Identifying this change requires genomic testing of the tumour. The account highlights that research tends to measure success by survival statistics, while patients often place equal or greater importance on quality of life during treatment. The person also reflects on the loss of other patients whose cancers did not respond as durably, which researchers are still working to understand. This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-10-23How a targeted drug kept one patient alive 15 years — but failed to save her friends